Base period: maintenance service for illumina equipment and associated instrumentation in support of NIH/NCI/CCR/genetics branch
Ended Purchase Order Awarded Last action
- Contract number
- 75N91021P00602
- Awardee
-
Illumina, Inc. UEI KMW3CRWNAAF3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $508,452
Award facts
- Opportunity
-
- Maintenance Service for Illumina Sequencing Equipment and Associated Instrumentation Solicitation · 75N91021Q00087 · Posted Jul 29, 2021
- Procurement of Maintenance Service for Illumina Sequencing Equipment and Associated Instrumentation Award Notice · Posted Sep 8, 2021
- Contract value 86% obligated
-
- $508,452.13 Current, with exercised options
- $589,617.13 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 811219 Other Electronic and Precision Equipment Repair and Maintenance
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 2 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20892, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $76,634 | |
| Exercise an Option | $135,808 | |
| Funding Only Action | -$44,024 | |
| Exercise an Option | $172,231 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $167,803 |
About this award
The National Cancer Institute within the National Institutes of Health awarded a $589,617.13 firm fixed-price purchase order to Illumina, Inc. on September 1, 2021, for maintenance services supporting genomic sequencing equipment at its Bethesda, Maryland facility. The contract covers preventative maintenance and emergency support for seven Illumina sequencers and associated instrumentation used by the NCI's Genetics Branch to advance cancer research and genomic analysis capabilities. This award was issued without a set-aside designation following a competitive solicitation process, with Illumina selected as the sole contractor based on its specialized expertise in maintaining its proprietary sequencing platforms. The ultimate completion date is August 31, 2026, encompassing multiple fiscal years of critical laboratory support.
The contract includes exercisable options extending the service period, including Option 3 (September 1, 2024–August 31, 2025), which was executed with updated scope adjustments to remove retired equipment in alignment with operational efficiency initiatives. Illumina, Inc., a San Diego-based biotechnology company specializing in next-generation sequencing systems and bioinformatics solutions, serves as the prime contractor with no identified subcontractors on this award. The company maintains extensive federal contracting relationships across multiple civilian agencies, including a $45 million Indefinite Delivery/Indefinite Quantity contract with the U.S. Department of Agriculture and numerous task orders with the Department of Veterans Affairs and other research institutions, positioning it as a critical technology provider for federally-funded genomic research initiatives.
Quick answers
Who was awarded contract 75N91021P00602?
75N91021P00602 was awarded to Illumina, Inc. by National Cancer Institute (National Institutes of Health) on September 1, 2021.
How much is contract 75N91021P00602 worth?
The government has obligated $508,452 on 75N91021P00602. Its potential value, with all options, is $589,617.
Was contract 75N91021P00602 competed?
The extent of competition for 75N91021P00602 was competed under sap. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award